Skip to content
Screener

Revolution Medicines, Inc. RVMD Total Liabilities & Equity

Total Liabilities & Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$87.63B-7.4%
Eli Lilly logo
Eli LillyLLY
$116.58B+30.4%
Pfizer logo
PfizerPFE
$207.62B-0.2%
Merck & Co. logo
Merck & Co.MRK
$128.69B+11.8%
Amgen logo
AmgenAMGN
$95.64B+8.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$1.37B+55.5%

Other financials

Income statement

See full
Revenue-
Operating income-$445.2M-84.9%
Net income-$453.8M-113%
EPS (diluted)-$2.29-103%

Balance sheet

See full
Cash & equivalents$440.9M+32.2%
Total debt$156.6M+16.6%
Total equity$1.5B-27.8%
Total assets$2.3B-4.7%

Cash flow

See full
Operating cash flow-$354.2M-82.2%
CapEx$1.5M-52.9%
Free cash flow-$355.7M-79.9%

Valuation

See full
Market cap$38.79B+460%
Enterprise value$38.5B+479%

Profitability

See full
Operating margin-88,031.9%-89,488pp
Net margin-76,423.3%-77,733pp
FCF margin-74,273.9%-75,457pp

Returns & leverage

See full
Return on equity-76.7%-923pp
Debt / equity0.1×0.0×
Current ratio6.8×-6.7×

Where this comes from

Reported directly by Revolution Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Revolution Medicines, Inc.’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:10 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-208969
Line itemMarch 31, 2026December 31, 2025
Stockholdersʼ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; none issued and outstanding at March 31, 2026 and December 31, 2025, respectively
Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 200,178,626 and 197,001,401 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively1919
Additional paid-in capital4,823,4384,497,143
Accumulated other comprehensive income (loss)(622)3,237
Accumulated deficit(3,322,918)(2,869,102)
Total stockholdersʼ equity1,499,9171,631,297
Total liabilities and stockholdersʼ equity$2,253,737$2,354,508

Item 1. Financial Statements.

FAQ

What is Revolution Medicines, Inc.'s total liabilities & equity?
Revolution Medicines, Inc. (RVMD) reported total liabilities & equity of $2.25B in Q1 2026.
How has Revolution Medicines, Inc.'s total liabilities & equity changed year-over-year?
Revolution Medicines, Inc.'s total liabilities & equity decreased by 4.7% year-over-year, from $2.37B to $2.25B.
What is the long-term trend for Revolution Medicines, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Revolution Medicines, Inc.'s total liabilities & equity has grown at a 32.9% compound annual growth rate (CAGR), from $567.4M to $2.35B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Revolution Medicines, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude